RAF1 S257L/S259F hotspot mutations: functional characterization and intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma.

Abstract excerpt

Constitutive activation of the MAPK pathway is a hallmark of melanoma, leading to aberrant cell proliferation and survival. Although oncogenic mutations in NRAS and BRAF are well established, the functional and therapeutic significance of RAF1 mutations remains incompletely defined. Here, we identify RAF1 S257L and S259F as recurrent hotspot mutations in melanoma by integrating our hospital cohort with TCGA-SKCM....

Topics

• Humans
• Melanoma
• Drug Resistance, Neoplasm
• Proto-Oncogene Proteins c-raf
• Mutation
• Cell Proliferation